Olema Pharmaceuticals, Inc.
General ticker "OLMA" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $450.6M (TTM average)
Olema Pharmaceuticals, Inc. follows the US Stock Market performance with the rate: 37.5%.
Estimated limits based on current volatility of 1.8%: low 16.25$, high 16.86$
Factors to consider:
- Total employees count: 96 (+29.7%) as of 2024
- Top business risk factors: No commercial products, Capital raising, Regulatory and compliance, Geopolitical risks, Supply chain disruptions
- Price in estimated range
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [11.89$, 31.80$]
- 2026-12-31 to 2027-12-31 estimated range: [7.94$, 21.92$]
Financial Metrics affecting the OLMA estimates:
- Negative: with PPE of -14.9 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -6.10 <= 0.07
- Negative: negative Net income
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Negative: Shareholder equity ratio, % of 89.71 > 64.25
Short-term OLMA quotes
Long-term OLMA plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $104.96MM | $142.26MM | $178.70MM |
| Operating Income | $-104.96MM | $-142.26MM | $-178.70MM |
| Non-Operating Income | $8.31MM | $12.78MM | $16.25MM |
| R&D Expense | $86.14MM | $124.52MM | $157.70MM |
| Income(Loss) | $-96.66MM | $-129.47MM | $-162.45MM |
| Profit(Loss)* | $-96.66MM | $-129.47MM | $-162.45MM |
| Stockholders Equity | $253.90MM | $408.96MM | $478.56MM |
| Assets | $276.94MM | $450.98MM | $533.43MM |
| Operating Cash Flow | $-83.73MM | $-104.35MM | $-146.72MM |
| Capital expenditure | $0.00MM | $0.16MM | $0.00MM |
| Investing Cash Flow | $-4.85MM | $-93.53MM | $-155.76MM |
| Financing Cash Flow | $133.41MM | $268.82MM | $211.30MM |
| Earnings Per Share** | $-2.14 | $-2.20 | $-1.87 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.